REG - JP Morgan Sec LLC Xeris Pharmaceutical - Xeris Pharmaceuticals, Inc 8.3

Xeris Biopharma HoldingsAnnouncement

09/08/2021 14:25

RNS Number : 0474I
  
J.P. Morgan Securities LLC
  
09 August 2021
  
 

Ap19
 
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


J.P. Morgan Securities LLC




Company dealt in


Xeris Pharmaceuticals, Inc.




Class of relevant security to which the dealings being disclosed relate (Note 2)


$0.001 common stock




Date of dealing


06 August 2021




 
2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


4,004,791                6.02


134,463             0.20




(2) Derivatives (other than options)


124,443                0.19


 




(3) Options and agreements to purchase/sell


 


 




Total


4,129,234             6.21


134,463             0.20



 
 
 
 
 
 
 




 

 
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




 
Purchase/sale


 
Number of relevant securities


 
Price per unit (USD)
 
(Note 5)




Purchases
 
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales


1,770,701 
 
 1,500 
 1,700 
 100 
 52,776 
 799 
 700 
 21,146 
 378 
 4,878 
 22,327 
 3,814 
 2,699 
 2,495 
 13,813 
 1,869 
 38,178 
 36,716 
 23,900 
 22,938 
 2,964 
 5,800 
 23,489 
 1,257 
 11,666 
 3,198 
 21,336 
 19,376 
 30,753 
 6,845 
 13,200 
 7,502 
 14,350 
 5,926 
 3,641 
 5,822 
 3,952 
 6,377 
 11,000 
 4,357 
 2,151 
 5,000 
 3,900 
 1,500 
 57,400 
 5,145 
 12,384 
 193 
 1,099 
 29,593 
 900 
 18,018 
 693 
 10,768 
 19,067 
 5,307 
 1,460 
 2,780 
 1,100 
 4,119 
 799 
 3,446


2.4000          USD
                        
2.3100          USD
2.3125          USD
2.3150          USD
2.3156          USD
2.3187          USD
2.3200          USD
2.3204          USD
2.3250          USD
2.3300          USD
2.3306          USD
2.3332          USD
2.3339          USD
2.3350          USD
2.3358          USD
2.3400          USD
2.3401          USD
2.3429          USD
2.3442          USD
2.3450          USD
2.3500          USD
2.3502          USD
2.3509          USD
2.3513          USD
2.3541          USD
2.3542          USD
2.3550          USD
2.3572          USD
2.3573          USD
2.3600          USD
2.3609          USD
2.3622          USD
2.3627          USD
2.3634          USD
2.3650          USD
2.3690          USD
2.3700          USD
2.3748          USD
2.3750          USD
2.3763          USD
2.3800          USD
2.3850          USD
2.3867          USD
2.3903          USD
2.3950          USD
2.4000          USD
2.4035          USD
2.4050          USD
2.4100          USD
2.4135          USD
2.4144          USD
2.4183          USD
2.4200          USD
2.4207          USD
2.4263          USD
2.4312          USD
2.4438          USD
2.4500          USD
2.4550          USD
2.5200          USD
2.5250          USD
2.5300          USD




 
 
 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(USD) (Note 5)




 


 


 


 




 
 
 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 




 
                          
 
Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and 
any other person relating to the voting rights of any relevant securities under any option referred to 
on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 
which any derivative referred to on this form is referenced. If none, this should be stated.
 
     None
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


 09 August 2021




Contact name


Alwyn Basch




Telephone number


0207 742 7407




If a connected EFM, name of offeree/offeror with which connected


N/A




If a connected EFM, state nature of connection (Note 10)


N/A




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ISEZZGGRFLGGMZM